MYCN's role in neuroblastoma treatment through SUMOylation inhibition
MYCN drives a druggable SUMOylation program in neuroblastoma
This study is looking at how a specific gene linked to high-risk neuroblastoma affects cancer growth and how well a new drug works to treat it, with the hope of finding better treatment options for children battling this tough cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11004253 on NIH RePORTER |
What this research studies
This research investigates how MYCN, a gene often amplified in high-risk neuroblastoma, influences cancer progression and treatment response. The study aims to explore the effectiveness of a new drug that inhibits SUMOylation, a process that may help in targeting the cancer's core regulatory mechanisms. By using patient-derived models, the research will assess the safety and efficacy of this treatment both alone and in combination with existing therapies. The goal is to identify a promising therapeutic strategy for children suffering from this aggressive form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with high-risk neuroblastoma, particularly those with MYCN amplification.
Not a fit: Patients with neuroblastoma who do not have MYCN amplification or those over the age of 11 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for high-risk neuroblastoma, potentially improving survival rates for affected children.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in neuroblastoma, indicating that this approach may be viable.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Faber, Anthony Charles — Virginia Commonwealth University
- Study coordinator: Faber, Anthony Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.